Gyroscope Therapeutics
Thomas Hallam is a Senior Scientist II at Novartis Institutes for BioMedical Research (NIBR), where research focuses on novel targets and technology for treating retinal disease. Hallam has a robust background, having served as a Senior Research Associate at Gyroscope Therapeutics, and previously held postdoctoral positions at Newcastle University and Catalyst Biosciences. Hallam's academic credentials include a PhD from Newcastle University, awarded for work on the genetic aspects of age-related macular degeneration, and a Master's in Neuroscience from the University of Southampton. Additionally, Hallam has experience in undergraduate research, working on neurodegenerative diseases and advanced imaging techniques.
This person is not in the org chart
Gyroscope Therapeutics
Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing gene therapy beyond rare diseases to treat a leading cause of blindness, dry age-related macular degeneration (AMD).